mRNA technology has emerged as a transformative force in the biopharmaceutical industry, enabling groundbreaking therapies and vaccines, including those for COVID-19.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Advanced Therapies Week 2025 in Dallas, TX
read moreAdvanced therapies, particularly cell and gene therapies, are ushering in a new era of personalized medicine, offering hope for patients with previously untreatable diseases.
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWorking in a Biotech Manufacturing Organization means joining a team of talented professionals focused on innovation, continuous growth, and a shared mission to improve lives.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to 12th International mRNA Health Conference 2024 in Boston, MA
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to 1st Annual Meeting AMM ASCENT in Boston, MA
read moreAnemocyte offers plasmid DNA (pDNA) manufacturing covering R&D, High Quality and GMP needs providing solutions that support every stage of therapy development while ensuring rigorous quality and traceability.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to European Society of Gene & Cell Therapy 2024 in Rome, Italy
read moreQuality assurance (QA) is crucial in the manufacturing of plasmid DNA (pDNA), a key component in gene therapy, vaccine development, genome editing, and synthetic biology.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
